Results 1 to 6 of 6

Thread: Praxis Biotechnology develops potentially groundbreaking Rosacea Medication

  1. #1
    Junior Member
    Join Date
    May 2017
    Posts
    19
    Country: Sweden

    Default Praxis Biotechnology develops potentially groundbreaking Rosacea Medication


  2. #2
    Senior Member
    Join Date
    Feb 2013
    Location
    Europe
    Posts
    176

    Default

    "They’ve developed a topical medication targeting a specific protein that is found in the skin of people with rosacea."
    Interestingly, what kind of protein?

  3. #3
    Junior Member
    Join Date
    May 2017
    Posts
    19
    Country: Sweden

    Default

    Quote Originally Posted by buratino29 View Post
    "They’ve developed a topical medication targeting a specific protein that is found in the skin of people with rosacea."
    Interestingly, what kind of protein?
    Good question. I guess it could be some kind of PRR / Toll Like Receptor.

    Actually there is another simular company called Dermata, who is working on their future Topical to, called DMT 210 which downregulates Toll Like Receptors e.t.c:
    http://www.dermatarx.com/new-index/

  4. #4
    Senior Member
    Join Date
    Feb 2013
    Location
    Europe
    Posts
    176

    Default

    Thanks Ralbihn for great finds. Those are interesting developments. But let’s keep in mind that Praxis Biotechnology is a start-up. Hope they will be able to raise enough money to carry on with the research.
    Dermata states “DMT210 has demonstrated downregulation of TLR2, lowering IL-8 production.* In addition, DMT210 also exhibited a reduction in IL-6, which is a powerful inflammatory mediator. “
    As far as I understand those receptors interfere with immune system. That would require them to go through rigorous tests before any approval is granted.
    All in all, I think a new research direction is starting to shape. It looks like a dull vasoconstrictor line of research is over.
    Let's keep an eye on them.

  5. #5
    Senior Member
    Join Date
    Apr 2015
    Posts
    432

    Default

    Very good! I say, where can I invest?

  6. #6
    Junior Member
    Join Date
    May 2017
    Posts
    19
    Country: Sweden

    Default Praxis Biotechnology 2020, Update from Dr. Wladis

    Email update from Dr. Edward J. Wladis about how things are going with Praxis Biotechnology and its development;

    We are still very excited to begin testing our medication. Currently, we are handling the regulatory burdens that are necessary prior to beginning our trial. I certainly hope to begin in the next few months,
    Last edited by Ralbihn; 22nd February 2020 at 03:15 PM.

Similar Threads

  1. Replies: 0
    Last Post: 30th June 2017, 11:40 AM
  2. Replies: 0
    Last Post: 1st February 2017, 09:00 PM
  3. Replies: 0
    Last Post: 26th April 2016, 04:00 PM
  4. Replies: 1
    Last Post: 25th August 2014, 02:03 PM
  5. Replies: 0
    Last Post: 27th September 2013, 07:00 AM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •